This document provides information about an upcoming conference on immunogenicity taking place June 13-14, 2016 in London. It lists the schedule, speakers, and topics to be covered over the two days. The conference will explore approaches to standardizing immunogenicity assays, unwanted immunogenicity, integrating immunogenicity risk data to predict clinical outcomes, and other topics related to assessing and reducing the immunogenicity of biotherapeutics. Registration discounts are available by March 31st or April 29th. The conference is aimed at accelerating the commercialization of next generation biotherapeutics by adopting advanced immunogenicity assessments.
SMi’s 3rd annual conference
Immunogenicity
13th and 14th June 2016, Holiday In Kensington Forum, London, UK.
Immunogenicity of an antigen is frequently encountered in the context of vaccine development, an area of intense interest currently due to the emergence or re-emergence of infectious pathogens with the potential for worldwide spread. With the global vaccine market expected to reach $84.44 billion by 2022, now is the time engage with industry experts to addresses the real challenges with immunogenicity including assay assessment, the role of aggregation, the introduction of nanobodies and many more!
For further information or to register please visit the event website www.immuno.co.uk or contact Matthew Apps on +44 (0) 207 827 6093 or mapps@smi-online.co.uk
This document summarizes key information about biological drugs and biosimilars, including:
1) It defines biologicals as drugs derived from biological sources using biotechnology like recombinant DNA or monoclonal antibody techniques. Biologicals have higher molecular weights and more complex structures than traditional drugs.
2) Immunogenicity, or the potential to provoke an immune response, is a major difference between biologicals and traditional drugs and can reduce efficacy of biologicals.
3) Several studies found biosimilars of biological drugs like alpha interferon and alpha erythropoietin showed differences in quality, efficacy, and safety compared to reference products in some cases.
4) Antibodies developed against biologicals can
Immunogenicity overview of therapeutic biologicsCreative-Biolabs
The sildes is created by Creative Biolabs. What is immunogenicity? Background of immunogenicity, importance of immunogencity in drug discovery are described in the presentation.
This document provides an agenda for the 2nd annual conference on immunogenicity taking place from June 29-30, 2015 in London. The conference will focus on understanding and modulating immunity in therapeutics, and exploring techniques to induce tolerance. It will include sessions on clinical directions, assays and assessments, with speakers from industry and academia. An interactive workshop on tools for early immunogenicity risk assessment will also be held on July 1.
This document provides information about an upcoming conference on immunogenicity taking place from June 12-13, 2017 in London. The conference will focus on standardizing immunogenicity methods, regulatory considerations, novel approaches to reducing immunogenicity, developments for biologic drugs and immunogenicity predictions, and emerging solutions. It lists the program agenda with topics such as predictive tools for immunogenicity, reporting clinically relevant data, cut point setting, EU guidance, ADA-dependent reactions, personalizing therapy, tolerogenic nanoparticles, and a panel on human versus humanized antibodies. Speakers are from organizations like Regeneron, NIBSC, EpiVax, Novartis, Abbvie, Merck, Roche, and Immun
This document provides information about the ADC Summit conference to be held on May 23-24, 2016 in London. It includes:
- An agenda for the two-day conference featuring presentations and workshops on topics related to antibody-drug conjugates (ADCs), including developments, innovations, challenges and lessons learned.
- Information about two half-day post-conference workshops on May 25th regarding ADC payloads and developments in high potency API manufacturing.
- Details on registration, discounts, speakers, sponsors and exhibition opportunities for the conference.
PEGS Europe Protein & Antibody Engineering Summit 2014 AgendaNicole Proulx
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. With two consecutive years of 40% growth in attendance, and another year of expanded program coverage, this year’s event will feature:
•500 attendees
•150 technical presentations
•70+ scientific posters
•40+ sponsors & exhibitors
•Dedicated networking opportunities
•Exclusive exhibit & poster hours
•Interactive roundtable, breakout & panel discussions
Highly Potent Active Pharmaceutical Ingredients 2017Fateja Begum
This document advertises a conference on Highly Potent Active Pharmaceutical Ingredients to be held May 22-24, 2017 in London. The conference will address containment strategies, cross contamination risks, challenges in scaling up potent compounds, improving CMO strategies, and risk assessment. Two half-day workshops will also be held on preventing cross contamination and employee exposures, and on conducting risk assessments for HPAPIs using a HAZOP methodology. The conference aims to help participants balance safety, quality and cost-effectiveness when working with highly potent compounds.
SMi’s 3rd annual conference
Immunogenicity
13th and 14th June 2016, Holiday In Kensington Forum, London, UK.
Immunogenicity of an antigen is frequently encountered in the context of vaccine development, an area of intense interest currently due to the emergence or re-emergence of infectious pathogens with the potential for worldwide spread. With the global vaccine market expected to reach $84.44 billion by 2022, now is the time engage with industry experts to addresses the real challenges with immunogenicity including assay assessment, the role of aggregation, the introduction of nanobodies and many more!
For further information or to register please visit the event website www.immuno.co.uk or contact Matthew Apps on +44 (0) 207 827 6093 or mapps@smi-online.co.uk
This document summarizes key information about biological drugs and biosimilars, including:
1) It defines biologicals as drugs derived from biological sources using biotechnology like recombinant DNA or monoclonal antibody techniques. Biologicals have higher molecular weights and more complex structures than traditional drugs.
2) Immunogenicity, or the potential to provoke an immune response, is a major difference between biologicals and traditional drugs and can reduce efficacy of biologicals.
3) Several studies found biosimilars of biological drugs like alpha interferon and alpha erythropoietin showed differences in quality, efficacy, and safety compared to reference products in some cases.
4) Antibodies developed against biologicals can
Immunogenicity overview of therapeutic biologicsCreative-Biolabs
The sildes is created by Creative Biolabs. What is immunogenicity? Background of immunogenicity, importance of immunogencity in drug discovery are described in the presentation.
This document provides an agenda for the 2nd annual conference on immunogenicity taking place from June 29-30, 2015 in London. The conference will focus on understanding and modulating immunity in therapeutics, and exploring techniques to induce tolerance. It will include sessions on clinical directions, assays and assessments, with speakers from industry and academia. An interactive workshop on tools for early immunogenicity risk assessment will also be held on July 1.
This document provides information about an upcoming conference on immunogenicity taking place from June 12-13, 2017 in London. The conference will focus on standardizing immunogenicity methods, regulatory considerations, novel approaches to reducing immunogenicity, developments for biologic drugs and immunogenicity predictions, and emerging solutions. It lists the program agenda with topics such as predictive tools for immunogenicity, reporting clinically relevant data, cut point setting, EU guidance, ADA-dependent reactions, personalizing therapy, tolerogenic nanoparticles, and a panel on human versus humanized antibodies. Speakers are from organizations like Regeneron, NIBSC, EpiVax, Novartis, Abbvie, Merck, Roche, and Immun
This document provides information about the ADC Summit conference to be held on May 23-24, 2016 in London. It includes:
- An agenda for the two-day conference featuring presentations and workshops on topics related to antibody-drug conjugates (ADCs), including developments, innovations, challenges and lessons learned.
- Information about two half-day post-conference workshops on May 25th regarding ADC payloads and developments in high potency API manufacturing.
- Details on registration, discounts, speakers, sponsors and exhibition opportunities for the conference.
PEGS Europe Protein & Antibody Engineering Summit 2014 AgendaNicole Proulx
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. With two consecutive years of 40% growth in attendance, and another year of expanded program coverage, this year’s event will feature:
•500 attendees
•150 technical presentations
•70+ scientific posters
•40+ sponsors & exhibitors
•Dedicated networking opportunities
•Exclusive exhibit & poster hours
•Interactive roundtable, breakout & panel discussions
Highly Potent Active Pharmaceutical Ingredients 2017Fateja Begum
This document advertises a conference on Highly Potent Active Pharmaceutical Ingredients to be held May 22-24, 2017 in London. The conference will address containment strategies, cross contamination risks, challenges in scaling up potent compounds, improving CMO strategies, and risk assessment. Two half-day workshops will also be held on preventing cross contamination and employee exposures, and on conducting risk assessments for HPAPIs using a HAZOP methodology. The conference aims to help participants balance safety, quality and cost-effectiveness when working with highly potent compounds.
SMi proudly presents due to the huge success of our Pharmaceutical Microbiology UK event the launch of SMi's Pharmaceutical Microbiology USA Conference in San Diego on 8th and 9th June 2017. Latest reports show that global rapid microbiology tests market to reach a net worth USD 19.5 Bn by 2022.* With the field growing at such a rapid rate SMi would like to take this opportunity to invite you to join us as we address the hot topics of the industry such as RMM, low endotoxin recovery, risk assessment and many more! With the forthcoming changes to annexe 1, take this opportunity to hear direct regulatory feedback and benchmark your strategies amongst industry peers. Our 2 day event will include presentations from both regulatory and industry experts sharing recent case studies and developing trends in the field of pharmaceutical microbiology
This document is a program for the 3rd annual ADC Summit 2014 conference on antibody-drug conjugates taking place from May 19-21, 2014 in London. The conference will feature presentations from industry experts on topics related to developing antibody-drug conjugates, including payloads, linkers, manufacturing, and clinical trials. Attendees can learn about the latest developments and network with other professionals in the field. A pre-conference workshop on May 21st will focus on early phase development considerations for antibody-drug conjugates to support first-in-human clinical trials.
SMi Group's Pharmaceutical Microbiology USA 2017 conferenceDale Butler
This document provides information on the Pharmaceutical Microbiology USA conference happening on June 7-9, 2017 in San Diego. The conference will address current challenges in sterility assurance, environmental monitoring, and rapid microbial methods. It will feature presentations and panel discussions from industry experts on topics like challenges in microbial control, environmental monitoring trends, rapid microbial testing validation, data integrity, and contamination issues. Attendees can choose from pre-conference workshops on technologies for monitoring contamination control or microbial required use for terminal sterilization. The conference aims to evaluate the latest trends and opportunities in microbial control for pharmaceutical manufacturing.
This document provides information about the Cell & Gene Therapy conference taking place on October 10-11, 2018 in London. It includes details about the agenda, speakers, workshops, and registration information. The two-day conference will focus on topics related to manufacturing, regulation, and translational research of cell and gene therapies. There will be presentations from industry experts on developing stem cell and gene therapies, as well as workshops on practical development issues and competitive intelligence in the cell and gene therapy field.
SMi will host the 7th Pharmaceutical Microbiology West Coast conference on June 8-9, 2017 in San Diego, USA. The conference will address current challenges in sterility assurance, environmental monitoring, and rapid microbial methods. Over the two days, experts from companies like GSK, Amgen, Janssen, and Takeda will discuss topics like environmental monitoring trends and data analysis, challenges in endotoxin testing and sterility assurance, case studies on contamination control, and the validation and use of rapid microbial methods. Workshops on the day before will cover technologies for monitoring contamination control and case studies, as well as microbial requirements for terminal sterilization.
This document summarizes an upcoming conference on superbugs and superdrugs taking place March 25-26, 2015 in London. The conference will focus on the latest developments in antibacterial therapies, funding, and partnerships to address antibiotic resistance. Over the two days, the conference will feature speakers from industry and academia discussing topics such as new business models for antibiotic development, clinical trials of new treatments, and partnerships between government and private organizations. Attendees can choose from two pre-conference workshops on designing antimicrobials for future needs and licensing an antibiotic. The conference is aimed at professionals involved in antibiotic research, development and related fields.
This document provides information about the 4th annual ADC Summit 2015 conference organized by SMi that will take place from May 18-19, 2015 in London. The conference will focus on advancing antibody-drug conjugate (ADC) and radioimmunotherapy (RIT) therapies, with sessions on payload development, clinical trials of ADCs, small molecule approaches, and intellectual property issues. There will also be a half-day workshop on May 20 about the regulatory requirements and development process for ADCs.
SMi’s 4th annual Peptides conference will give you the perfect platform to network, collaborate and learn over 2 days, featuring various key presentations by senior level industry professionals. With topics such as peptide formulation and delivery, as well as new advances in alternative peptide analysis technologies, Cell Penetrating Peptides, enhancements in synthesis mechanisms, analytical monitoring techniques, and many more.
This document provides information about an upcoming conference on peptide therapeutics taking place on July 6-7, 2017 in London. It includes the following key details:
- The conference will focus on the latest advances in peptide discovery, development and delivery to accelerate progress in the field. It will include sessions on topics like protein-protein interactions, peptide characterization, and strategies for half-life extension.
- Speakers will represent major pharmaceutical companies and present case studies on developing peptide drugs. There will also be workshops on July 5th covering topics like quality by design in manufacturing and oral delivery of peptides.
- Attendees can save money by registering before certain deadlines in March, April and May. The event
This document discusses biological monitoring (BM) guidance values and their uses and requirements. It provides the following key points:
1) BM is a tool for assessing exposure that is used by occupational health providers, hygienists, employers, researchers and regulators to evaluate compliance, exposure controls, and identify potential health issues.
2) Guidance values are set by various organizations using different methods, and the same substance may have different values. Exceeding a value indicates exposure controls should be examined and exposure reduced.
3) Requirements for BM include ethics, appropriate sample matrices, analytes related to toxicity, and validated analytical methods. Guidance values also require data linking BM levels to exposure, health effects, and
SMi Group's Pharma Microbiology East Coast 2019 - updated Feb 2019Dale Butler
This document provides information about the Pharmaceutical Microbiology East Coast conference taking place from April 10-12, 2019 in Boston, USA. The conference will discuss best practices and techniques for tackling microbial control challenges in the pharmaceutical industry. Over the two-day conference and optional workshops on the third day, topics will include regulatory considerations, environmental monitoring, rapid microbial methods, sterility assurance, case studies, and risk mitigation strategies. Speakers will represent major pharmaceutical companies and provide insights on the latest industry issues and solutions. Attendees can gain expertise on key microbiological topics relevant for pharmaceutical manufacturing and product development.
This 3-day event is the meeting place for international and domestic scientists to share case studies and project updates, showcase new techniques and form collaborations that pave the way towards the future of China’s biopharmaceutical industry.
SMi Group's Pharmaceutical Microbiology West Coast 2020 conferenceDale Butler
This document provides information on the Pharmaceutical Microbiology West Coast conference happening June 17-19, 2020 in San Diego. It outlines the chairs, speakers, highlights and agenda for the event. The conference will focus on novel approaches and best practices for tackling current industry contamination control challenges, and will include sessions on contamination control, guidance and regulations, detection and identification methods, and supporting pharmaceutical facilities and novel therapeutics. There will also be an optional pre-conference workshop on data integrity in environmental monitoring.
This document provides an overview and agenda for the 2nd annual conference on drug discovery taking place on March 21st-22nd, 2018 in London. The conference will feature presentations and discussions on:
1) New technologies to improve discovery cycles in chemistry and drug discovery processes, including the role of artificial intelligence and new modalities like PROTACs and antibodies.
2) Advances in small molecule therapeutics from Roche and challenges in validating targets with CRISPR from Epizyme.
3) The role of open access chemical probes from the SGC and how Bayer uses them in drug discovery.
4) How artificial intelligence can transform drug design and discovery efforts at companies like Exscient
SMi Group's Pharmaceutical Microbiology East Coast 2019 Dale Butler
This document provides information on the Pharmaceutical Microbiology East Coast conference taking place from April 10-11, 2019 in Boston, USA. It includes details on registration, chairpersons, key speakers and their topics. The conference will discuss challenges in pharmaceutical microbiology such as regulatory changes, environmental monitoring, rapid methods and sterility assurance. There will also be workshops on April 12th on mold contamination challenges and microbiological control using vapor phase hydrogen peroxide bio-decontamination. The event is aimed at professionals working in pharmaceutical microbiology.
The document announces the 5th Annual Pharmacovigilance Conference to be held from March 17-19, 2010 in London. It will discuss implementing best practices in drug safety and surveillance. Key topics include evaluation of risk mitigation strategies, classification of adverse drug reactions, pharmacovigilance in clinical trials, proposals from the EU Commission's "Pharma Package", and developing training programs for global pharmacovigilance systems. The conference will provide insights and best practices in pharmacovigilance from leaders in the industry.
SMi Group's Pharmaceutical Microbiology East Coast 2017 conferenceDale Butler
This document provides information on a workshop titled "Navigating the requirements of a modern QC Microbiology Laboratory" that will be held on November 15th, 2017. The workshop will introduce approaches for blending traditional and cutting-edge microbiology methodologies both in the laboratory and for manufacturing monitoring programs. It will also provide practical solutions for common laboratory issues and expectations for building quality into pharmaceutical products. The workshop will be led by Vanessa Vasadi-Figueroa and Robert Ferer and cover topics such as modernizing laboratories, real-time release testing, data integrity, and training new talent.
Saudi arabien erinnert an seine felsenfeste position gegenüber der marokkanis...Tanja Seidemann
Der saudische Minister für Auswärtiges, Herr Adel al-Joubeir, bekräftigte, dass die Position seines Landes gegenüber der marokkanischen Sahara eine felsenfeste Position sei und es die marokkanischen Bemühungen zwecks der Schlichtung der Frage im Rahmen des marokkanischen Autonomievorschlags unter der Ägide der Vereinten Nationen unterstütze.
The document discusses the origins and evolution of rock and roll music. It mentions that rock and roll originated from blues, rhythm and blues, and country music styles. Over time, the term "rock" came to be used to refer to modern styles derived from rock and roll, while "rock and roll" specifically refers to the original rhythm that emerged in the 1950s. It lists some subgenres that originated from rock like jazz rock, progressive rock, punk rock, heavy metal, blues rock, and country rock.
SMi proudly presents due to the huge success of our Pharmaceutical Microbiology UK event the launch of SMi's Pharmaceutical Microbiology USA Conference in San Diego on 8th and 9th June 2017. Latest reports show that global rapid microbiology tests market to reach a net worth USD 19.5 Bn by 2022.* With the field growing at such a rapid rate SMi would like to take this opportunity to invite you to join us as we address the hot topics of the industry such as RMM, low endotoxin recovery, risk assessment and many more! With the forthcoming changes to annexe 1, take this opportunity to hear direct regulatory feedback and benchmark your strategies amongst industry peers. Our 2 day event will include presentations from both regulatory and industry experts sharing recent case studies and developing trends in the field of pharmaceutical microbiology
This document is a program for the 3rd annual ADC Summit 2014 conference on antibody-drug conjugates taking place from May 19-21, 2014 in London. The conference will feature presentations from industry experts on topics related to developing antibody-drug conjugates, including payloads, linkers, manufacturing, and clinical trials. Attendees can learn about the latest developments and network with other professionals in the field. A pre-conference workshop on May 21st will focus on early phase development considerations for antibody-drug conjugates to support first-in-human clinical trials.
SMi Group's Pharmaceutical Microbiology USA 2017 conferenceDale Butler
This document provides information on the Pharmaceutical Microbiology USA conference happening on June 7-9, 2017 in San Diego. The conference will address current challenges in sterility assurance, environmental monitoring, and rapid microbial methods. It will feature presentations and panel discussions from industry experts on topics like challenges in microbial control, environmental monitoring trends, rapid microbial testing validation, data integrity, and contamination issues. Attendees can choose from pre-conference workshops on technologies for monitoring contamination control or microbial required use for terminal sterilization. The conference aims to evaluate the latest trends and opportunities in microbial control for pharmaceutical manufacturing.
This document provides information about the Cell & Gene Therapy conference taking place on October 10-11, 2018 in London. It includes details about the agenda, speakers, workshops, and registration information. The two-day conference will focus on topics related to manufacturing, regulation, and translational research of cell and gene therapies. There will be presentations from industry experts on developing stem cell and gene therapies, as well as workshops on practical development issues and competitive intelligence in the cell and gene therapy field.
SMi will host the 7th Pharmaceutical Microbiology West Coast conference on June 8-9, 2017 in San Diego, USA. The conference will address current challenges in sterility assurance, environmental monitoring, and rapid microbial methods. Over the two days, experts from companies like GSK, Amgen, Janssen, and Takeda will discuss topics like environmental monitoring trends and data analysis, challenges in endotoxin testing and sterility assurance, case studies on contamination control, and the validation and use of rapid microbial methods. Workshops on the day before will cover technologies for monitoring contamination control and case studies, as well as microbial requirements for terminal sterilization.
This document summarizes an upcoming conference on superbugs and superdrugs taking place March 25-26, 2015 in London. The conference will focus on the latest developments in antibacterial therapies, funding, and partnerships to address antibiotic resistance. Over the two days, the conference will feature speakers from industry and academia discussing topics such as new business models for antibiotic development, clinical trials of new treatments, and partnerships between government and private organizations. Attendees can choose from two pre-conference workshops on designing antimicrobials for future needs and licensing an antibiotic. The conference is aimed at professionals involved in antibiotic research, development and related fields.
This document provides information about the 4th annual ADC Summit 2015 conference organized by SMi that will take place from May 18-19, 2015 in London. The conference will focus on advancing antibody-drug conjugate (ADC) and radioimmunotherapy (RIT) therapies, with sessions on payload development, clinical trials of ADCs, small molecule approaches, and intellectual property issues. There will also be a half-day workshop on May 20 about the regulatory requirements and development process for ADCs.
SMi’s 4th annual Peptides conference will give you the perfect platform to network, collaborate and learn over 2 days, featuring various key presentations by senior level industry professionals. With topics such as peptide formulation and delivery, as well as new advances in alternative peptide analysis technologies, Cell Penetrating Peptides, enhancements in synthesis mechanisms, analytical monitoring techniques, and many more.
This document provides information about an upcoming conference on peptide therapeutics taking place on July 6-7, 2017 in London. It includes the following key details:
- The conference will focus on the latest advances in peptide discovery, development and delivery to accelerate progress in the field. It will include sessions on topics like protein-protein interactions, peptide characterization, and strategies for half-life extension.
- Speakers will represent major pharmaceutical companies and present case studies on developing peptide drugs. There will also be workshops on July 5th covering topics like quality by design in manufacturing and oral delivery of peptides.
- Attendees can save money by registering before certain deadlines in March, April and May. The event
This document discusses biological monitoring (BM) guidance values and their uses and requirements. It provides the following key points:
1) BM is a tool for assessing exposure that is used by occupational health providers, hygienists, employers, researchers and regulators to evaluate compliance, exposure controls, and identify potential health issues.
2) Guidance values are set by various organizations using different methods, and the same substance may have different values. Exceeding a value indicates exposure controls should be examined and exposure reduced.
3) Requirements for BM include ethics, appropriate sample matrices, analytes related to toxicity, and validated analytical methods. Guidance values also require data linking BM levels to exposure, health effects, and
SMi Group's Pharma Microbiology East Coast 2019 - updated Feb 2019Dale Butler
This document provides information about the Pharmaceutical Microbiology East Coast conference taking place from April 10-12, 2019 in Boston, USA. The conference will discuss best practices and techniques for tackling microbial control challenges in the pharmaceutical industry. Over the two-day conference and optional workshops on the third day, topics will include regulatory considerations, environmental monitoring, rapid microbial methods, sterility assurance, case studies, and risk mitigation strategies. Speakers will represent major pharmaceutical companies and provide insights on the latest industry issues and solutions. Attendees can gain expertise on key microbiological topics relevant for pharmaceutical manufacturing and product development.
This 3-day event is the meeting place for international and domestic scientists to share case studies and project updates, showcase new techniques and form collaborations that pave the way towards the future of China’s biopharmaceutical industry.
SMi Group's Pharmaceutical Microbiology West Coast 2020 conferenceDale Butler
This document provides information on the Pharmaceutical Microbiology West Coast conference happening June 17-19, 2020 in San Diego. It outlines the chairs, speakers, highlights and agenda for the event. The conference will focus on novel approaches and best practices for tackling current industry contamination control challenges, and will include sessions on contamination control, guidance and regulations, detection and identification methods, and supporting pharmaceutical facilities and novel therapeutics. There will also be an optional pre-conference workshop on data integrity in environmental monitoring.
This document provides an overview and agenda for the 2nd annual conference on drug discovery taking place on March 21st-22nd, 2018 in London. The conference will feature presentations and discussions on:
1) New technologies to improve discovery cycles in chemistry and drug discovery processes, including the role of artificial intelligence and new modalities like PROTACs and antibodies.
2) Advances in small molecule therapeutics from Roche and challenges in validating targets with CRISPR from Epizyme.
3) The role of open access chemical probes from the SGC and how Bayer uses them in drug discovery.
4) How artificial intelligence can transform drug design and discovery efforts at companies like Exscient
SMi Group's Pharmaceutical Microbiology East Coast 2019 Dale Butler
This document provides information on the Pharmaceutical Microbiology East Coast conference taking place from April 10-11, 2019 in Boston, USA. It includes details on registration, chairpersons, key speakers and their topics. The conference will discuss challenges in pharmaceutical microbiology such as regulatory changes, environmental monitoring, rapid methods and sterility assurance. There will also be workshops on April 12th on mold contamination challenges and microbiological control using vapor phase hydrogen peroxide bio-decontamination. The event is aimed at professionals working in pharmaceutical microbiology.
The document announces the 5th Annual Pharmacovigilance Conference to be held from March 17-19, 2010 in London. It will discuss implementing best practices in drug safety and surveillance. Key topics include evaluation of risk mitigation strategies, classification of adverse drug reactions, pharmacovigilance in clinical trials, proposals from the EU Commission's "Pharma Package", and developing training programs for global pharmacovigilance systems. The conference will provide insights and best practices in pharmacovigilance from leaders in the industry.
SMi Group's Pharmaceutical Microbiology East Coast 2017 conferenceDale Butler
This document provides information on a workshop titled "Navigating the requirements of a modern QC Microbiology Laboratory" that will be held on November 15th, 2017. The workshop will introduce approaches for blending traditional and cutting-edge microbiology methodologies both in the laboratory and for manufacturing monitoring programs. It will also provide practical solutions for common laboratory issues and expectations for building quality into pharmaceutical products. The workshop will be led by Vanessa Vasadi-Figueroa and Robert Ferer and cover topics such as modernizing laboratories, real-time release testing, data integrity, and training new talent.
Saudi arabien erinnert an seine felsenfeste position gegenüber der marokkanis...Tanja Seidemann
Der saudische Minister für Auswärtiges, Herr Adel al-Joubeir, bekräftigte, dass die Position seines Landes gegenüber der marokkanischen Sahara eine felsenfeste Position sei und es die marokkanischen Bemühungen zwecks der Schlichtung der Frage im Rahmen des marokkanischen Autonomievorschlags unter der Ägide der Vereinten Nationen unterstütze.
The document discusses the origins and evolution of rock and roll music. It mentions that rock and roll originated from blues, rhythm and blues, and country music styles. Over time, the term "rock" came to be used to refer to modern styles derived from rock and roll, while "rock and roll" specifically refers to the original rhythm that emerged in the 1950s. It lists some subgenres that originated from rock like jazz rock, progressive rock, punk rock, heavy metal, blues rock, and country rock.
Red dirt curriculum and national curriculum: how do they line up?Ninti_One
On 23 September 2015, the Remote Education Systems project presented in Adelaide on the topic of how the red dirt curriculum and national curriculum line up.
Este documento presenta los conceptos básicos de electrónica digital y tecnología de la información. Introduce las señales eléctricas analógicas y digitales, los sistemas numéricos binarios y decimales, las funciones lógicas y puertas lógicas, y los métodos para simplificar funciones lógicas como mapas de Karnaugh. El documento también describe los pasos para resolver problemas de electrónica digital utilizando tablas de verdad, mapas de Karnaugh y esquemas de puertas lógicas.
Tendance Marketing digital 2016 : le video marketingSWiTCH
78% des 15-24 ans consomment de la vidéo en ligne et 71% des entreprises américaines ont prévu d'augmenter leur budget consacré à la vidéo en 2016. Riposte au blocage des publicités, évolutions techniques et développement du streaming native, nous vous présentons les clés pour décrypter ce phénomène, les enjeux, les meilleures pratiques à adopter et les erreurs à éviter.
Simplifying Hadoop with RecordService, A Secure and Unified Data Access Path ...Cloudera, Inc.
SFHUG presentation from February 2, 2016. One of the key values of the Hadoop ecosystem is its flexibility. There is a myriad of components that make up this ecosystem, allowing Hadoop to tackle otherwise intractable problems. However, having so many components provides a significant integration, implementation, and usability burden. Features that ought to work in all the components often require sizable per-component effort to ensure correctness across the stack.
Lenni Kuff explores RecordService, a new solution to this problem that provides an API to read data from Hadoop storage managers and return them as canonical records. This eliminates the need for components to support individual file formats, handle security, perform auditing, and implement sophisticated IO scheduling and other common processing that is at the bottom of any computation.
Lenni discusses the architecture of the service and the integration work done for MapReduce and Spark. Many existing applications on those frameworks can take advantage of the service with little to no modification. Lenni demonstrates how this provides fine grain (column level and row level) security, through Sentry integration, and improves performance for existing MapReduce and Spark applications by up to 5×. Lenni concludes by discussing how this architecture can enable significant future improvements to the Hadoop ecosystem.
About the speaker: Lenni Kuff is an engineering manager at Cloudera. Before joining Cloudera, he worked at Microsoft on a number of projects including SQL Server storage engine, SQL Azure, and Hadoop on Azure. Lenni graduated from the University of Wisconsin-Madison with degrees in computer science and computer engineering.
SMi Group Soldier Equipment and Technology Advancement Forum 2016Dale Butler
This document provides information about the Soldier Equipment and Technology Advancement Forum (SETAF) 2016 conference to be held on March 14-15, 2016 in London. The conference will bring together military and industry experts to discuss optimizing soldier equipment strategies through knowledge sharing and networking. Over 20 hours of informal networking is scheduled. The agenda includes panels on soldier modernization efforts, industry developments in soldier equipment, and discussion groups on topics like night vision, power, lethality, survivability, and human factors. Senior military representatives from the US, UK, and Germany are scheduled to speak. The conference aims to advance dismounted capabilities and inform the soldier modernization process.
SMi Group's 5th annual Smart Water Systems 2016Dale Butler
This document provides information on the 5th annual Smart Water Systems conference taking place on April 25-26, 2016 in London. The conference will focus on investing in the benefits and overcoming challenges of smart water systems. Key sessions will address Thames Water's smart water efficiency project, smart water systems as a social necessity, domestic water metering in Ireland using automatic reading, and Southern Water's universal metering program. Featured speakers represent Thames Water, Irish Water, Southern Water, and other water companies. The conference will provide insights on customer engagement, data collection strategies, delivering benefits from smart metering, and utilizing big data analytics. A post-conference workshop on April 27th will focus on applying behavioral economics and randomized trials to energy
This document provides information about a conference on biosimilars taking place from September 30th to October 1st, 2015 in London. The conference will discuss the evolving regulatory landscape for biosimilar approval in the US and Europe, market access challenges, protein characterization, and analytical comparability. It includes an agenda with sessions on the regulatory processes, patent litigation, pharmacovigilance, clinical development strategies, and analytical techniques for assessing biosimilarity. Pre-conference and post-conference workshops will provide more in-depth discussions of these topics.
This document provides information about the Helicopter Technology Eastern Europe 2015 conference, which will take place June 24-25, 2015 in Prague, Czech Republic. It outlines the conference agenda, including keynote speeches from high-ranking military officials from across Eastern Europe on their countries' helicopter fleets and modernization plans. The document details the senior speaker lineup and sessions on topics like joint helicopter operations, future technologies, life cycle management, and individual countries' helicopter capabilities and priorities. The goal of the conference is to bring together senior military leaders, industry, and experts to collaborate on enhancing security and stability in Eastern Europe through discussions of military helicopter programs and capabilities.
The document announces a conference on satellite technological advancement for effective military communications in Asia to be held on May 14-15, 2014 at the Grand Copthorne Waterfront Hotel in Singapore. The conference will discuss topics such as regional military satellite communication roadmaps, technological advancements, US developments in the Pacific region, and commercial satellite communications. Speakers at the conference include military and industry representatives from countries across Asia and other regions.
Training and simulation for night vision systemsDale Butler
This document provides information about an upcoming masterclass on training and simulation for night vision systems hosted by Squadron Leader Douglas Vine. The masterclass will cover defining night vision training requirements, virtual terrain image generation systems for night vision training, and interactive mission-based night vision training scenarios. Attendees will learn about the latest night vision training technology and have the opportunity to provide input and ask questions. The target audience includes those from civil and military organizations conducting night vision operations such as search and rescue, police, and helicopter emergency services.
SMi Group's 7th annual Advances in Cell Based Assays conferenceDale Butler
This document summarizes a two-day conference on advances in cell-based assays being held on November 11-12, 2014 in London. The conference will explore the latest developments in cell-based assays and their application in drug discovery and development. Speakers will include representatives from pharmaceutical companies such as GSK, AstraZeneca, Novartis, UCB, and Merck Serono, as well as academics. Topics will include the use of cell-based assays in biologics drug discovery, challenges in validation and regulation, phenotypic screening, stem cell technologies, and 3D cell cultures. Workshops on leveraging cell-based assays for open innovation and evaluating cell-based assays in drug discovery will also be offered
SMi Group's 11th annual Military Space Situational AwarenessDale Butler
SMi Group's Military Space 2016 conference returns to London next March for its 11th year with a focus on identifying and maximising space situational awareness capabilities for the future
SMi Group's Defence Logistics Eastern Europe 2016Dale Butler
SMi Group returns to Defence Logistics with its inaugural Defence Logistics Eastern Europe 2016 conference and exhibition taking place in Prague next March
SMi Group's 2nd annual Helicopter Technology Eastern Europe 2016Dale Butler
The document advertises the Second Annual Helicopter Technology Eastern Europe conference taking place in Budapest, Hungary in May 2016. The conference will bring together senior military helicopter program managers and heads of air forces from Central and Eastern European countries to discuss modernizing helicopter technology and capabilities. It will include briefings from various heads of air forces and programs, as well as panels on cooperation, interoperability, survivability systems, and challenges and opportunities for modernizing defense helicopter fleets in the region.
SMi Group's 4th annual Lyophilisation Europe 2016 conferenceDale Butler
This document advertises an upcoming conference on lyophilisation (freeze drying) to be held in London from July 4-5, 2016. It provides an agenda for the two-day conference, listing topics such as designing robust freeze drying processes, continuous freeze drying, spray drying, and optimizing filling processes. It also advertises a half-day post-conference workshop on designing and scaling up a freeze drying process to be led by experts from NIBSC and Biopharma Process Systems. The document promotes the conference and workshop opportunities for professionals in lyophilisation, formulation development, bioprocessing and related fields.
This document provides information about an upcoming Immuno-Oncology conference, including workshops, speakers, and program details. The conference will take place September 25-27, 2018 in London and will feature discussions on novel targeted cancer therapies. It will include workshops on strategic intelligence in immuno-oncology and the microbiome's role in cancer immunotherapy. The two-day main conference will discuss topics like immune checkpoints, oncolytic viruses, bispecific antibodies, and combination therapies. It aims to foster thought-provoking discussions in this space.
This document provides information about an upcoming conference on immunogenicity hosted by SMi from July 14-16, 2014 in London, UK. The conference will focus on assessing early risks of immunogenicity, clinical implications, and strategies for evaluating and designing biologic therapeutics. Speakers will discuss topics like predictive tools for immunogenicity, inducing immunological tolerance, the immunogenicity of biosimilars, and more. The document also advertises two half-day post-conference workshops on July 16 about the clinical impact of immunogenicity and predictive tools, and the immunogenicity of biosimilars.
This document provides information about the 4th Annual Conference on Cancer Vaccines to be held on September 16-17, 2015 in London. Professor Farzin Farzaneh of Kings College London will chair the conference. Key topics to be addressed include tumour genetic heterogeneity in immunotherapy, combination therapies to advance immune-oncology vaccines, and developments in targeted and personalized cancer treatments. There will be presentations from industry and academic leaders in the field.
The document provides information about an upcoming conference on allergies to be held July 5-7, 2017 in London. It outlines the chair and keynote speakers at the conference, including representatives from pharmaceutical companies and research institutions. The conference will focus on strategies for tackling allergies, regulatory challenges, molecular diagnostics, biomarkers, and novel treatment approaches such as DNA vaccines and epicutaneous immunotherapy. Attendees can learn about innovative allergy research and standards, understand patient and industry perspectives, and network with global allergy experts.
SMi Group's Cancer Vaccines 2015 conferenceDale Butler
This document summarizes a conference on cancer vaccines taking place in September 2015 in London. The conference will address topics such as tumour genetic heterogeneity in immunotherapy, understanding the angiogenic process in tumours, and developing RNA vaccines and combination therapies to advance immune-oncology. A keynote speech will discuss using personalized dendritic cell vaccines to mobilize the immune system against solid tumour targets. The conference features workshops, speakers from industry and academia, and discussions on advancing personalised cancer treatment and improving targeted responses to tumours through immunotherapy and vaccine development.
SMi Group's Superbugs and Superdrugs USA 2018Dale Butler
This document provides information on the 3rd annual Superbugs & Superdrugs USA conference taking place November 12-13, 2018 in Iselin, New Jersey. Anthony Simon Lynch and William Weiss will chair the event. Featured speakers will discuss topics such as pathogen-focused drug development, antibiotic resistance, novel modes of action to overcome resistance, and new anti-fungal developments. Participants will learn about funding opportunities, rapid diagnostic methods, and case studies. Two half-day workshops on November 14 will focus on rapid diagnostics for drug resistance and challenges of commercializing new antibiotics. SCYNEXIS, Inc. is sponsoring the conference.
The document discusses challenges and opportunities in the development of biosimilars. It provides perspectives from several industry experts on the top hurdle being a lack of clarity around intellectual property and marketing strategies as well as high development costs. The experts note that developing the necessary skill sets around quality by design, analytics, and clinical trial design is key to overcoming hurdles in developing biosimilars safely and effectively.
Providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities, SMi presents the 20th annual Superbugs & Superdrugs conference which will return to Central London on 19th and 20th March 2018.
The threat of AMR is regularly making front page news but what is the industry actually doing? Are drug manufacturers any closer to finding a solution and how is the government helping? These will be just some of the questions answered through powerful keynote addresses delivered by an expert panel of scientific leaders, drug discovery specialists and government bodies such as MHRA and DNDi.
This document provides information about the 20th Annual Superbugs & Superdrugs conference on tackling antimicrobial resistance that will take place on March 19-21, 2018 in London. The conference will feature presentations on funding and regulatory approaches for new antibiotic development, strategies to combat resistant pathogens, and research on novel antibiotic candidates and alternatives. A half-day workshop on March 21st will provide an overview of using animal models in pre-clinical drug development.
Immunogenicity and Bioassay Summit, Baltimore, MD November 17-19, 2015David Cunningham
Thinking about attending the Immunogenicity and Bioassay Summit, but have questions? I would be more than happy to walk you through the program agenda, pricing options and answer any questions you may have. In the meantime, don’t forget about the savings deadline coming up Friday, October 16th!
Call David at 781-972-5472 if you would like to join us!
Imugene is developing B-cell peptide vaccines called mimotopes that induce a patient's own B-cells to produce antibodies targeting specific cancer antigens. Their lead candidate, HER-Vaxx, is a mimotope therapy for HER2-positive cancers that is designed to mimic the Herceptin antibody. A completed Phase 1 trial in breast cancer demonstrated HER-Vaxx was safe and induced anti-HER-2 antibodies and immune responses. Imugene is now conducting a Phase 1b/2 trial of HER-Vaxx in combination with chemotherapy in HER2-positive gastric cancer patients with results expected in 2018. The document provides an overview of Imugene's novel mimotope platform and its
SMi Group's 5th annual Cancer Vaccines 2016 conferenceDale Butler
This document provides information about a cancer vaccines conference, including two pre-conference workshops, being held on September 20-22, 2016 in London. The conference will focus on the latest advances in cancer vaccine development and preparation for commercialization of immunotherapy breakthroughs. The workshops on September 20th will address cancer vaccines and combination therapies as well as active immune therapy strategies for cancer. The two-day main conference on September 21-22nd will include sessions on biomarkers, dendritic cell vaccines, personalized therapies, RNA vaccines, and targeting strategies. Speakers will represent academic institutions and companies developing cancer immunotherapy technologies and therapies.
This document provides information about a cancer vaccines conference, including two pre-conference workshops on cancer vaccines and combination therapies. The conference will take place September 20-22, 2016 in London and focus on the latest advances in cancer vaccine development and commercialization. It lists the agenda and speakers for the two days of the main conference, which will cover topics like RNA-based vaccines, biomarkers, clinical trials, and combination therapies. Registration discounts are available before certain dates. The workshops on September 20th will address how cancer vaccines can work with and without other treatments to maximize efficacy against cancer.
In its third year, “PEGS China: Protein and Antibody Engineering & Development Summit” returns to Shanghai for 3 days of inspiring presentations and case studies featuring the latest trends and future potential of China’s biotech industry.
This year’s event comprises four content-driven conferences with over sixty global speakers, plus a new 1-day seminar on clinical & regulatory strategies for global and domestic IND and BLA filings. In addition, dedicated exhibit hall and poster viewing hours will provide invaluable opportunities for networking, deal-making and ideas exchange.
SMi Group's Pharmaceutical Microbiology UK 2020Dale Butler
This document provides information on the upcoming Pharmaceutical Microbiology UK conference in January 2020. The conference will focus on contamination control, environmental monitoring, and current regulatory expectations. It will feature speakers from pharmaceutical companies and regulatory agencies who will discuss topics such as the impact of revisions to Annex 1, strategies for effective environmental monitoring programs, and novel methods for rapid microbial detection. A post-conference workshop day will include interactive sessions on developing risk-based cleaning approaches, designing environmental monitoring programs, and rapid microbiological methods and testing.
SMi Group's 3rd annual Biosimilars North America 2016Dale Butler
This document provides information about the "3rd Annual Conference on Biosimilars North America" event happening on November 15-17, 2016 in Iselin, New Jersey. It includes details about pre-conference workshops, the speaker lineup, and session topics which will address regulatory considerations, commercialization strategies, and technological developments for biosimilars in the US. Registration discounts are offered before June 30th and September 30th. The event is aimed at solving challenges and accelerating commercialization of biosimilars in North America.
SMi Group's 7th annual Biosimilars Europe 2016 conferenceDale Butler
This document provides information about two pre-conference workshops for the 7th Annual Biosimilars Europe conference.
The first workshop focuses on maximizing intellectual property and regulatory rights related to biosimilars. It will cover topics like regulatory data protection, orphan drug exclusivity, supplementary protection certificates, and pediatric rewards. The workshop leaders are partners at Bristows LLP.
The second workshop examines how the payer environment for biosimilars is evolving. It will provide insight into pricing, reimbursement, and formulary access processes. Case studies will also be presented on successful biosimilar launches. The workshop leader is the director of RJW & Partners Ltd, a pricing and market
PEGS Boston the essential protein engineering summitNicole Proulx
With record-breaking attendance in 2015, PEGS Boston attracts an international delegation of nearly 2,000 participants including conference delegates, speakers, exhibitors, sponsors and guests representing over 30 countries.
Participants value the in-depth short courses, access to 22 conferences, and wide-ranging presentations delivering new unpublished data, case studies, innovation and insight.
The vast exhibit hall will be packed with 125 exhibiting companies and more than 200 research posters on display providing valuable viewing of innovative new technologies, as well as abundant networking with biopharma researchers and industry representatives.
We have 13 research and development projects within:
• Research
• Oncology
• Respiratory, Inflammation and Autoimmunity
• Cardiovascular and Metabolic Disease
• Antibody Discovery and Protein Engineering
• Pathology
• Biopharmaceutical Development
• Cell Culture and Fermentation Sciences
• Formulation Sciences
• Analytical Biotechnology Science
Similar to SMi Group's 3rd annual Immunogenicity 2016 conference (20)
SMi Group's Pre-filled Syringes West Coast 2020 conferenceDale Butler
This document provides an agenda for the 5th annual Pre-Filled Syringes West Coast conference taking place June 15-17, 2020 in San Diego, CA. The conference will focus on innovations in device design and technology, advances in human factors engineering, combination product regulatory insights, and design controls and risk management. It will feature presentations from industry leaders at companies like Genentech and AstraZeneca as well as regulators from the FDA. There will also be two post-conference workshops on June 17th focusing on navigating FDA requirements for connected devices and digital health, and post-market safety reporting for combination products.
SMi Group's Military Robotics and Autonomous Systems USA 2020 conferenceDale Butler
This document advertises the Military Robotics and Autonomous Systems USA conference happening on June 22-23, 2020 in Arlington, Virginia. Attendees can save $400 by registering by February 28, $200 by registering by March 31, and $100 by registering by April 30. The conference will discuss topics like US Army robotics programs, Australian Army robotics development, unmanned vehicle programs, robotics supporting warfighters' mobility and sustainability, and integrating robotics into ground formations. Speakers will include representatives from the US and Australian militaries as well as academics working on relevant research.
SMi Group's Future Soldier Technology USA 2020 conferenceDale Butler
The document announces the 2nd Annual Future Soldier Technology USA conference on June 8-10, 2020 in Arlington, Virginia. The conference will focus on modernizing equipment for dismounted soldiers and marines, and feature speakers from the US and other militaries involved in soldier technology programs. Over 150 attendees are expected to discuss initiatives like NGSW-AR/R/FC, ISSP, and manned-unmanned teaming to enhance soldier lethality, mobility, and situational awareness.
SMi Group's Military Space USA 2020 conferenceDale Butler
This document provides an agenda for the 2nd Annual Military Space USA Conference supporting the US military space enterprise. The conference will include presentations from senior leaders in the US Space Force, Air Force, and other allied militaries on topics such as space acquisition reform through SMC 2.0, training the future space warfighting force, and leveraging disruptive commercial space technologies. A separate focus day will explore experimental smallsat capabilities, export controls for space technologies, advanced propulsion concepts, using LEO mega-constellations for bandwidth, in-orbit manufacturing, and accelerating commercial innovation. The event aims to connect disruptors and innovators with government to integrate new technologies rapidly into military space operations.
This document summarizes a conference focused on helicopter technology for Central and Eastern Europe being held in Budapest, Hungary on May 20-21, 2020. It will feature keynote speeches from military leaders from Hungary, Slovakia, Romania, Germany, and Croatia on developments and modernization efforts of their national helicopter fleets. Technical experts from the US, UK, Netherlands, and Czech Republic will also present. Sessions will discuss regional cooperation and interoperability, training standards, and enhancing capabilities like search and rescue. The goal is focused discussion on challenges facing helicopter program managers and informal networking for participants.
This document provides information about an upcoming conference on future armoured vehicles in Central and Eastern Europe in 2020. It outlines early registration discounts that decrease over time, as well as special rates for military and government representatives. The document details benefits of attending the conference, including hearing updates from armed forces in the region. It lists speakers from various countries who will discuss topics like armoured vehicle programmes, enhancing capabilities, and ensuring interoperability. The agenda outlines presentations over two days covering issues like future infantry fighting vehicles, enhancing mechanization capabilities, and modernizing ground platforms. The document promotes sponsorship opportunities at the event.
SMi Group's Unmanned Maritime Systems 2020 conferenceDale Butler
This document provides information about the 4th Annual Unmanned Maritime Systems conference taking place on April 13-14, 2020 in London. It discusses key reasons to attend like hearing from naval officers on integrating unmanned assets and learning about updates on unmanned platforms, anti-submarine warfare, mine countermeasures, and technological innovation. The agenda outlines presentations and speakers from military organizations like the Royal Navy, US Navy, Spanish Navy, and NATO who will discuss topics like developing unmanned systems, accelerating unmanned technologies, and using unmanned systems for mine countermeasure operations.
SMi Group's Military PNT 2020 conferenceDale Butler
The document summarizes the agenda for the "Military PNT 2020" conference to be held on May 18-19 in London. The event highlights include briefings from the US DoD on GPS and NTS-3 programs, understanding requirements for operating in degraded PNT environments, and engaging with industry and military leaders. The agenda covers topics such as UK PNT strategies, warfighter PNT considerations, legal perspectives on PNT resilience, and GNSS interference case studies. Keynote speakers include representatives from the US Air Force, Lockheed Martin, UK MoD, DGA, NPL, and BHO Legal.
This document provides an agenda for the Defence Aviation Safety conference taking place on April 23-24, 2020 in London. The agenda includes keynote presentations and panels on topics related to ensuring safety across defence aviation programs and platforms. Speakers will represent organisations such as the UK Ministry of Defence, US Air Force, German Military Aviation Authority, and NATO. Presentation topics will cover safety priorities, certification processes, training, accident investigation and lessons learned. A closing panel on day two will discuss the challenges of ensuring military aviation safety and cyber resilience.
SMi Group's Pre-filled Syringes East Coast 2020 Dale Butler
This document announces an interactive workshop on combination product development taking place on April 29th, 2020 in Boston, USA. The workshop will consist of three sessions focused on key topics in combination product development: combination product development strategies, drug delivery device testing solutions, and human factors validation studies. Speakers will include experts from major pharmaceutical companies such as AstraZeneca, Eli Lilly, Biogen, and regulatory agencies. The workshop aims to provide attendees insights and strategies for navigating challenges in combination product development from concept to approval.
SMi Group's Air Mission Planning and Support 2020Dale Butler
The document announces an upcoming conference on "Maximising Air Power through the Development and Integration of Innovative Support Systems" to be held in London on April 21-22, 2020. The conference will examine developments in air mission planning and focus on data management, fifth generation integration, and multi-domain command and control. It will feature expert military speakers from countries like the UK, US, Canada, France, Hungary, and Belgium representing air forces, NATO, and DARPA to discuss challenges and solutions.
SMi Group's Military Robotics and Autonomous Systems 2020 Dale Butler
This document provides information about the 3rd Annual Military Robotics and Autonomous Systems conference taking place on April 1-2, 2020 in London. It outlines the key topics to be discussed including UK and international perspectives on robotic and autonomous systems programs and strategies. Speakers will address topics such as unmanned ground vehicle development, autonomy for military robotic systems, and manned-unmanned teaming. The conference will explore delivering quality robotic systems to enhance operational effectiveness and discuss technology demonstrations.
This document advertises the 6th Annual Future Soldier Technology conference taking place March 9-11, 2020 in London. The conference will focus on dismounted soldier and marine technology, discussing key areas like dismounted capability. Military, procurement, and research experts from around the world will present on their soldier programs, challenges, and successes. Attendees can learn the latest developments, network with key speakers and decision makers, and gather intelligence to inform their projects. The conference aims to allow information sharing on equipping soldiers to maintain an advantage against evolving adversaries.
This document provides information about the 5th Annual Defence Logistics Central & Eastern Europe conference taking place on March 3-4, 2020 in Budapest, Hungary. The summary includes:
- The conference will bring together senior military, government, and industry personnel from Central and Eastern Europe to discuss developments in defence logistics and increase cooperation in the region.
- Over the two days, there will be keynote briefings and panels on topics like modernizing logistics structures, interoperability, operational capabilities of country logistics divisions, and industry roles. Speakers will represent militaries like Hungary, Czech Republic, Poland, and industry sponsors.
- Attendees can benefit from networking opportunities and learning about log
The document announces Space Week, consisting of the Small Satellites Conference from April 27-28 and the Military Space Situational Awareness Conference from April 29-30 in London. It provides details on the conferences, including chairpersons, speakers from various space agencies, companies, and militaries, and topics to be discussed such as small satellites, space insurance, disruptive approaches to space, space data, and military space situational awareness. The document aims to invite colleagues to participate in Space Week to explore developments in small satellites and how to track and manage space assets.
SMi Group's Superbugs and Superdrugs 2020 conferenceDale Butler
This document provides information about the Superbugs & Superdrugs conference on March 30-31, 2020 in London. The conference will focus on non-traditional approaches to fighting antimicrobial resistance and will feature speakers from companies and organizations working on alternatives to antibiotics, including those developing antibacterial proteins, agents that neutralize bacterial virulence, direct lytic agents, and immunomodulatory therapies. It provides details on the agenda, speakers, workshops, registration and sponsorship opportunities.
SMi Group's AI in Drug Discovery 2020 conferenceDale Butler
This document provides information about an upcoming conference on AI in Drug Discovery taking place from March 16-17, 2020 in London, UK. It includes details about the program, speakers, registration fees and deadlines. The conference will explore how machine learning and AI are being applied across the drug discovery process, from compound design and virtual screening to toxicity prediction. There will be case studies presented from major pharmaceutical companies on their experience integrating AI. The document also advertises sponsorship opportunities for the event.
The document announces a conference on exploring the small satellite revolution and its impact on future space. It will be held on April 27-28, 2020 in London, UK and include a half-day post-conference workshop on April 29. The conference will discuss topics such as disruptive approaches to space, small satellite applications, space data and networking, insurance, and market trends and opportunities. It will feature expert speakers from organizations such as NASA, Surrey Satellite Technology, the Israeli Space Agency, US Air Force, and more. Attendees can learn about key small satellite programs and how these systems are transforming capabilities.
How to Fix the Import Error in the Odoo 17Celine George
An import error occurs when a program fails to import a module or library, disrupting its execution. In languages like Python, this issue arises when the specified module cannot be found or accessed, hindering the program's functionality. Resolving import errors is crucial for maintaining smooth software operation and uninterrupted development processes.
This presentation was provided by Steph Pollock of The American Psychological Association’s Journals Program, and Damita Snow, of The American Society of Civil Engineers (ASCE), for the initial session of NISO's 2024 Training Series "DEIA in the Scholarly Landscape." Session One: 'Setting Expectations: a DEIA Primer,' was held June 6, 2024.
How to Add Chatter in the odoo 17 ERP ModuleCeline George
In Odoo, the chatter is like a chat tool that helps you work together on records. You can leave notes and track things, making it easier to talk with your team and partners. Inside chatter, all communication history, activity, and changes will be displayed.
Walmart Business+ and Spark Good for Nonprofits.pdfTechSoup
"Learn about all the ways Walmart supports nonprofit organizations.
You will hear from Liz Willett, the Head of Nonprofits, and hear about what Walmart is doing to help nonprofits, including Walmart Business and Spark Good. Walmart Business+ is a new offer for nonprofits that offers discounts and also streamlines nonprofits order and expense tracking, saving time and money.
The webinar may also give some examples on how nonprofits can best leverage Walmart Business+.
The event will cover the following::
Walmart Business + (https://business.walmart.com/plus) is a new shopping experience for nonprofits, schools, and local business customers that connects an exclusive online shopping experience to stores. Benefits include free delivery and shipping, a 'Spend Analytics” feature, special discounts, deals and tax-exempt shopping.
Special TechSoup offer for a free 180 days membership, and up to $150 in discounts on eligible orders.
Spark Good (walmart.com/sparkgood) is a charitable platform that enables nonprofits to receive donations directly from customers and associates.
Answers about how you can do more with Walmart!"
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UPRAHUL
This Dissertation explores the particular circumstances of Mirzapur, a region located in the
core of India. Mirzapur, with its varied terrains and abundant biodiversity, offers an optimal
environment for investigating the changes in vegetation cover dynamics. Our study utilizes
advanced technologies such as GIS (Geographic Information Systems) and Remote sensing to
analyze the transformations that have taken place over the course of a decade.
The complex relationship between human activities and the environment has been the focus
of extensive research and worry. As the global community grapples with swift urbanization,
population expansion, and economic progress, the effects on natural ecosystems are becoming
more evident. A crucial element of this impact is the alteration of vegetation cover, which plays a
significant role in maintaining the ecological equilibrium of our planet.Land serves as the foundation for all human activities and provides the necessary materials for
these activities. As the most crucial natural resource, its utilization by humans results in different
'Land uses,' which are determined by both human activities and the physical characteristics of the
land.
The utilization of land is impacted by human needs and environmental factors. In countries
like India, rapid population growth and the emphasis on extensive resource exploitation can lead
to significant land degradation, adversely affecting the region's land cover.
Therefore, human intervention has significantly influenced land use patterns over many
centuries, evolving its structure over time and space. In the present era, these changes have
accelerated due to factors such as agriculture and urbanization. Information regarding land use and
cover is essential for various planning and management tasks related to the Earth's surface,
providing crucial environmental data for scientific, resource management, policy purposes, and
diverse human activities.
Accurate understanding of land use and cover is imperative for the development planning
of any area. Consequently, a wide range of professionals, including earth system scientists, land
and water managers, and urban planners, are interested in obtaining data on land use and cover
changes, conversion trends, and other related patterns. The spatial dimensions of land use and
cover support policymakers and scientists in making well-informed decisions, as alterations in
these patterns indicate shifts in economic and social conditions. Monitoring such changes with the
help of Advanced technologies like Remote Sensing and Geographic Information Systems is
crucial for coordinated efforts across different administrative levels. Advanced technologies like
Remote Sensing and Geographic Information Systems
9
Changes in vegetation cover refer to variations in the distribution, composition, and overall
structure of plant communities across different temporal and spatial scales. These changes can
occur natural.
How to Build a Module in Odoo 17 Using the Scaffold MethodCeline George
Odoo provides an option for creating a module by using a single line command. By using this command the user can make a whole structure of a module. It is very easy for a beginner to make a module. There is no need to make each file manually. This slide will show how to create a module using the scaffold method.
How to Make a Field Mandatory in Odoo 17Celine George
In Odoo, making a field required can be done through both Python code and XML views. When you set the required attribute to True in Python code, it makes the field required across all views where it's used. Conversely, when you set the required attribute in XML views, it makes the field required only in the context of that particular view.
Executive Directors Chat Leveraging AI for Diversity, Equity, and InclusionTechSoup
Let’s explore the intersection of technology and equity in the final session of our DEI series. Discover how AI tools, like ChatGPT, can be used to support and enhance your nonprofit's DEI initiatives. Participants will gain insights into practical AI applications and get tips for leveraging technology to advance their DEI goals.
This slide is special for master students (MIBS & MIFB) in UUM. Also useful for readers who are interested in the topic of contemporary Islamic banking.
हिंदी वर्णमाला पीपीटी, hindi alphabet PPT presentation, hindi varnamala PPT, Hindi Varnamala pdf, हिंदी स्वर, हिंदी व्यंजन, sikhiye hindi varnmala, dr. mulla adam ali, hindi language and literature, hindi alphabet with drawing, hindi alphabet pdf, hindi varnamala for childrens, hindi language, hindi varnamala practice for kids, https://www.drmullaadamali.com
1. www.immuno.co.uk
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
ACADEMIC & GROUP DISCOUNTS AVAILABLE
A: Approaches to standardising assays for measuring drug levels
and anti drug antibodies to biotherapeutics in clinical practice
Workshop Leaders:
Hishani Kirby, Founder and Director, Hishani Kirby Associates Ltd
Daniel Sikkema, Executive Director, Head of Immunogenicity
and Clinical Immunology, GlaxoSmithKline
08.30 – 12.30
B: Unwanted immunogenicity from
bench to bedside
Workshop Leaders:
Arno Kromminga, CEO/CSO, IPM Biotech
Sofie Pattijn, Chief Technology Officer, ImmunXperts
13.30 – 17.30
PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS
Wednesday 15th June 2016, Holiday Inn Kensington Forum, London, UK
REGISTER BY 31ST MARCH AND RECEIVE A £400 DISCOUNT
REGISTER BY 29TH APRIL AND RECEIVE A £200 DISCOUNT
@SMIPHARM
#immunosmi
SMi Present the 3rd Annual Conference on…
Immunogenicity
Holiday Inn Kensington Forum, London, UK
13 - 14
JUNE
2016
Accelerating commercialisation of your
next gen biotherapeutics – adopt advanced
immunogenicity assessments for successful
regulatory approval
Key Sessions:
• MHRA: Towards harmonisation of immunogenicity assays
• Integration of immunogenicity risk data to forecast clinical
outcomes
• A harmonised approach to interpretation and reporting of
clinical immunogenicity data
• Development and validation of cell based antibody
neutralisation assays
Sponsored by
Chairs for 2016:
Annie De Groot,
CEO and CSO,
EpiVax, Inc.
Adnan Khan,
Senior Scientist Immunology/Pharmacology,
UCB
Featured Speakers:
• Meenu Wadhwa, Section Leader, Cytokines and Growth
Factors, NIBSC, MHRA
• Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
• Daniel Sikkema, Executive Director, Head of Immunogenicity
and Clinical Immunology, GlaxoSmithKline
• Jochem Gokemeijer, Associate Director, Bristol-Myers Squibb
• Tim Hickling, Immunogenicity Sciences Discipline Lead, Pfizer
2. Immunogenicity
Day One | Monday 13th June 2016
Register online at: www.immuno.co.uk • Alternatively fax your
Sponsored by
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
Annie De Groot, CEO and CSO, EpiVax, Inc.
OPENING ADDRESS
09.10 Improving the efficacy and safety profile of
biotherapeutics by addressing product immunogenicity
with tolerogenic nanoparticles
• The development of anti-drug antibodies (ADAs) is
a common cause for treatment failure and adverse
events associated with biologic therapies.
• Addressing product immunogenicity has the potential
to improve efficacy and safety profile of novel biologics;
reduce catastrophic late stage clinical failure due
to ADAs; provide life cycle management for existing
products; and differentiate products from biosimilars.
• Selecta Biosciences is a clinical stage company that
has developed a novel platform of Synthetic Vaccine
Particles (SVP) to induce durable antigen-specific
immune tolerance for the prevention of ADAs
Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
09.50 Redefining the well-defined: unwanted immune responses
• What is an unwanted immune response?
• What can we define as tolerance?
• Therapeutic innervation and innovation
Adnan Khan, Senior Scientist Immunology/Pharmacology, UCB
10.30 Morning Coffee
11.00 A harmonised approach to interpretation and reporting of
clinical immunogenicity data
• How can we harmonise data?
• Should we be able to compare trial results that use
different ranking methods
• The benefits a harmonised approach can bring to the
reporting of clinical immunogenicity data
Daniel Sikkema, Executive Director, Head of
Immunogenicity and Clinical Immunology,
GlaxoSmithKline
KEYNOTE ADDRESS
11.40 Towards harmonisation of immunogenicity assays
• Wide variation in ADA incidence and titres often
reported for a therapeutic
• Should we produce reference panels or standardise
methods to harmonise data?
• Availability of a WHO reference panel for erythropoietin
antibody assays
Meenu Wadhwa, Section Leader, Cytokines and Growth
Factors, NIBSC, MHRA
12.20 Networking Lunch
13.20 Immunogenicity risk assessment tools for biologics
• Immunogenicity risk assessment tools to inform biologics
development programs
• Utilisation of immunogenicity tools to guide critical
quality attributes (CQA) for product attributes
• Challenges in clinical validation of immunogenicity risk
assessment
Jochem Gokemeijer, Associate Director, Bristol-Myers Squibb
14.00 Integrating best-in-class in vitro and ex vivo assays to
manage immunogenicity risk in biologics
• Learn how data from cell-based assays, physical
MHC-peptide binding assays and mass spectrometry
antigen presentation assays can be integrated to
characterize immune responses against, or caused by,
biotherapeutic drugs
• Mitigate the risk of first infusion reactions using whole-
blood cytokine release assay
• Improve decision-making in lead selection, lead
characterisation and re-engineering options
Jeremy Fry, Director of Sales, ProImmune Ltd.
14.40 Afternoon Tea
15.10 Nanobodies, a promising new class of
biopharmaceuticals. What about their immunogenicity?
• Nanobodies originate from camelids, but does their
humanisation make sense?
• Different methods for anti-drug antibodies (ADA)
assessment towards nanobodies
• In vitro immunogenicity risk assessment of nanobodies
Chloé Ackaert, Postdoctoral Researcher,
Free University of Brussels
15.50 Understanding the role of aggregation in the
immunogenicity of biotherapeutic proteins
• Comparison of the immunological responses to
immunisation with recombinant biologics in monomeric
and aggregated forms in a mouse model
• The results were generally indicative of skewing towards
a Th1-type response
• Can HCPs also play a role in modulating the immune
response?
Jeremy Derrick, Professor, University of Manchester
16.30 Chairman’s Closing Remarks and Close of Day One
Annie De Groot, CEO and CSO, EpiVax, Inc.
Abzena offers a suite of complementary services
and technologies. Its range of technologies
include immunogenicity assessment, antibody drug
conjugation, protein engineering, PEGylation, cell
line development, GMP manufacturing and a range
of bespoke assays to enables the development
of better biopharmaceuticals which will have a
greater chance of reaching the market.
www.abzena.com
Sponsorship and Exhibition Opportunities
SMi offer sponsorship, exhibition, advertising
and branding packages, uniquely tailored
to complement your company’s marketing
strategy. Prime networking opportunities exist to
entertain, enhance and expand your client base
within the context of an independent discussion
specific to your industry.
Should you wish to join the increasing number
of companies benefiting from sponsoring our
conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or
email: amalick@smi-online.co.uk
EXPLORING IMMUNOGENIC ASSESSMENT TECHNIQUES
NEXT GENERATION BIOLOGICS
3. Immunogenicity
Day Two | Tuesday 14th June 2016
08.30 Registration and Coffee
09.00 Chairman’s Opening Remarks
Adnan Khan, Senior Scientist Immunology/Pharmacology, UCB
OPENING ADDRESS / KEYNOTE ADDRESS
09.10 Development and validation of cell based antibody
neutralisation assays
• Examples of validation of cell based neutralisation
assays
• Their application to release / stability testing of vaccines
• Consideration of the assay life cycle
Sue Charlton, Scientific Lead, Vaccine Research Group,
Public Health England
09.50 Integration of immunogenicity risk data to forecast clinical
outcomes
• Immune responses to biologics as a normal response to
drug exposure
• Identifying key risk factors for immunogenicity
• Working with protein engineers to reduce
immunogenicity of biotherapeutics
• Utilising non-clinical assays for immunogenicity
assessment
Tim Hickling, Immunogenicity Sciences Discipline Lead, Pfizer
10.30 Morning Coffee
11.00 Influence of aggregates on in vitro T cell responses
• Immunogenicity of therapeutic protein products can
elicit unwanted ADA
• Protein aggregation can result in enhanced
immunogenicity
• In vitro methods that measure the impact of these
aggregates on enhanced immunogenicity will be useful
tools in screening processes to avoid or reduce problems
associated with ADA
Mark Fogg, Immunology Group Leader, Abzena
11.40 T-cell amplification assays for immunogenicity prediction:
T-cell repertoire and epitopes
• Why are T cell assays performed to predict
immunogenicity?
• What kind of data do they produce?
• Do they have been already confronted to clinical
observations?
• Are they really useful as compared to other predictive
approaches?
Machteld Tiemessen, Senior Scientist, Janssen
12.20 Networking Lunch
13.20 Correlation of T-cell responses induced by therapeutic
cancer vaccines with clinical responses
• In premalignant disease caused by high risk HPV,
therapeutic vaccination-induced T-cell responses
correlate with clinical responses
• In late stage HPV-induced cancer myeloid cell
depletion by standard chemotherapy fosters robust
vaccine-induced T cell responses
• Therapeutic vaccines works as monotherapy in pre-
malignant disease, but treatment of late stage cancer
requires combination of vaccination with immuno-
modulation
Kees Melief, Chief Scientific Officer, ISA Pharmaceuticals
Ronald Loggers, Chief Executive Officer, ISA Pharmaceuticals
14.00 A computational pipeline for personalised cancer vaccine
development
• Checkpoint inhibitors are changing cure rates for
cancer and generating excitement in the cancer field
• While cure rates are improving, personalised cancer
vaccines may improve cure rates even further
• Personalised cancer vaccines are feasible using
available computational tools
• Participants will learn how personalised cancer vaccines
will move the needle on cancer cures of the future
Annie De Groot, CEO, EpiVax
14.40 Afternoon Tea
15.10 Immunogenicity of biosimilar monoclonal antibodies
• Unexpected immunogenicity linked to biosimilar
monoclonal antibodies
• The challenge of assessing similarity between originator
and biosimilar mAb
• Developing a characteriation strategy for proving
comparability with biosimilars
Andreas Herrmann, CEO, Baliopharm AG
15.50 Protein aggregates: Why do we need to study them?
Quantification and characterisation of sub-visible particles
in protein therapeutics
• Biopharmaceutical and problems never seen with non-
protein substances
• Protein aggregates structure and function
• Strategy in analysis and characterization of protein
aggregates
Mantas Malisauskas, Manager R&D, Baxalta
16.30 Chairman’s Closing Remarks and Close of Day Two
Adnan Khan, Senior Scientist Immunology/Pharmacology, UCB
registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
Want to know how you can get involved? Interested in promoting your services to this market?
Contact Anna Serazetdinova, SMi Marketing on +44 (0) 207 827 6180 or email: aserazetdinova@smi-online.co.uk
Supported by
A CLOSER LOOK AT ADAPTIVE T CELLS
INNOVATIONS IN IMMUNOGENICITY
Official Publications
4. A: Approaches to standardising assays
for measuring drug levels and anti drug
antibodies to biotherapeutics in
clinical practice
Workshop Leaders:
Hishani Kirby, Founder and Director,
Hishani Kirby Associates Ltd
Daniel Sikkema, Executive Director, Head of Immunogenicity
and Clinical Immunology, GlaxoSmithKline
HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 15th June 2016
08.30 – 12.30
Holiday Inn Kensington Forum, London, UK
Overview of Workshop:
The assay requirements for rapid decision making with licenced
biotherapeutics in clinical practice can be very different from the
bestpracticeappliedduringregulatedstudies.Thegrowingtrend
for therapeutic drug monitoring (TDM) with biotherapeutics has
highlighted the need for harmonisation of assays and associated
data throughout the lifecycle of a given drug.
In this workshop, an overview of historical approaches to
validating methods to quantify biopharmaceuticals and to
detect, monitor, and characterise anti-drug antibodies will
be presented. The current best practices, terminology, and
future insights for standardisation of methods and associated
technological developments will be discussed.
You will be able to learn about the latest trends and
developments for quantifying biotherapeutics and monitoring
anti-drug antibodies will be presented in the context of assay
harmonisation, associated challenges and possible solutions.
Programme:
08.30 Registration
09.00 Workshop Leaders Introduction
09.10 Overview of historical approaches for drug and ADA
measurement: Fit for purpose?
• Which format?
• What are the parameters?
• Constraints and challenges
10.30 Morning Coffee
11.00 Looking beyond – technological developments
• Future standardisation of methods
• Advanced quantification techniques for
biotherapeutics and
application on immunogenicity
• Associated challenges and solutions
12.00 Q&A
12.30 End of Workshop
About the Workshop Leader:
Hishani Kirby, PhD, Founder and Director,
Hishani Kirby Associates Ltd
With over 25years in the biopharmaceutical industry,
Hishani has gained wide experience in the development of
biopharmaceutical products. This has been mainly with Mab and
Mab-basedfragments,whereshehasutilisedherextensiveprotein
analytical and bioanalytical expertise, in the characterisation and
measurement of complex biotherapeutics. Hishani first estalished
her career at Celltech in Mab therapeutics and then joined UCB,
where she was responsible for providing expert guidance on
bioanalytical strategy in PK, PD and immunogenicity in support of
the company’s portfolio from discovery through to post licencing
phases of development, as well as leading the team responsible
for execution of analytical and bioanalytical services.
More recently, Hishani has formed her own consulting
company providing expertise in scientific aspects of bioanalysis,
immunogenicity risk assessment and testing strategies, and in
regulatory considerations in biopharmaceutical development.
Her strengths are in designing and implementing practical/
innovative analytical solutions to enable rapid decision making
through development to post license life cycle management.
DanielSikkema,ExecutiveDirector,HeadofImmunogenicityand
Clinical Immunology, GlaxoSmithKline
DanjoinedGlaxoSmithKline(GSK)asExecutiveDirectorandHead
oftheClinicalImmunologygroupinBioPharmR&DinAugust2010.
Priortothis,hehadheldvariouspositionsofincreasingresponsibility
at Bristol-Myers Squibb, Wyeth Vaccines, Merck Vaccines and
Biologics, and Sanofi Pasteur. Dan has contributed to the clinical
immunology and microbiology assessments leading to licensure
of Prev(e)nar, Meningitec, Gardasil, Rotavax, ProQuad, and
Zostavax, and has worked extensively with the WHO, US Centers
for Disease Control, National Institute for Biological Standards
and Controls, US FDA, and EMA. Now at GSK he is heading
the Immunogenicity and Clinical Immunology group assessing
immunogenicity of administered biotherapeutics and the
quantitation of target-engaged biomarkers in the clinical setting,
aswellasleadingtheInnovativeMedicinesInitiative(www.abirisk.
eu) to further understand the underlying mechanisms and basic
biology around induction of immunogenicity to biotherapeutics
and their clinical relevance. July 1, 2015, he assumed the Chair
Elect position for Division V at American Society for Microbiology.
5. B: Unwanted immunogenicity from
bench to bedside
Workshop Leaders:
Arno Kromminga, CEO/CSO, IPM Biotech
Sofie Pattijn, Chief Technology Officer, ImmunXperts
HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 15th June 2016
13.30 – 17.30
Holiday Inn Kensington Forum, London, UK
Overview of Workshop:
This workshop will give an insight on the rapid growing
field of unwanted immunogenicity and the science
behind it. The immunology of an unwanted immune
response will be addressed and discussed. Also,
an overview of the tools for early immunogenicity
assessment will be given. Finally, the emerging trends
and clinical impact of neutralising anti-drug antibodies
will be discussed followed by a summary of the lessons
learned and future challenges.
Programme:
13.30 Registration
14.00 The immunology of immunogenicity
14.45 Tools for early non-clinical immunogenicity
assessment
15.30 Afternoon Tea
16.00 Neutralising anti-drug antibodies:
Emerging trends and clinical impact
16.45 Lessons learned and future challenges
17.20 Closing remarks
17.30 Close of workshop
About the Workshop Leaders:
Dr Arno Kromminga is currently CSO of GLP-certified
IPM Biotech. In addition, he is a faculty member at
the Institute of Immunology at the University of Kiel. He
studied Biochemistry and Immunology and has 20+
years experience in assay development, is author of
multiple publications in peer-reviewed journals and
books and is a co-founder and board member of
the European Immunogenicity Platform (EIP). He and
his team have developed and validated numerous
immunological binding and cellular functional assays
for immunogenicity testing and PK/PD analysis for pre-
clinical and clinical studies. His major interest besides
the validation of assays, is the interpretation of results to
obtain clinically meaningful data
Sofie Pattijn (CTO, ImmunXperts) has over 20 years of
experience in the field of immunogenicity assessment
(vaccines and biotherapeutics). She has extensive
hands-on lab experience and has managed and
coached several In Vitro teams over the last decade.
From 2008 till 2013 she was Head of the In Vitro
Immunogenicity group at AlgoNomics (Ghent, Belgium)
and Lonza Applied Protein Services (Cambridge, UK).
Prior to that, she worked at Innogenetics, Belgium for
over 15 years.
6. Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferencesdocumentationviatheDocumentPortaltoanydelegatewhohaspaidbutisunable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able
to provide documentation in these circumstances. We cannot accept cancellations of orders
placed for Documentation or the Document Portal as these are reproduced specifically to order.
If we have to cancel the event for any reason, then we will make a full refund immediately, but
disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about
other products and services. Unless you tick here □ we may also share your data with third parties
offeringcomplementaryproductsorservices.Ifyouhaveanyqueriesorwanttoupdateanyofthe
data that we hold then please contact our Database Manager databasemanager@smi-online.
co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your
address on the attached letter.
Payment must be made to SMi Group Ltd, and received before the event, by one of the
following methods quoting reference P-176 and the delegate’s name. Bookings made within
7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on Document portal and literature distribution for all UK customers and for those EU
Customers not supplying a registration number for their own country here.
______________________________________________________________________________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
□ Book by 31st March to receive £400 off the conference price
□ Book by 29th April to receive £200 off the conference price
EARLY BIRD
DISCOUNT
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference & 2 Workshops £2697.00 + VAT £3236.40
□ Conference & 1 Workshop A □ B □ £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ 2 Workshops £1198.00 + VAT £1437.60
□ 1 Workshop only £599.00 + VAT £718.80
Workshop A □ Workshop B □
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712
I cannot attend but would like to purchase access to the following
Document Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
Unique Reference Number
Our Reference LVP-176
DELEGATE DETAILS
Terms and Conditions of Booking
PAYMENT
VAT
CONFERENCE PRICES
DOCUMENTATION
VENUE Holiday Inn Kensington Forum, 97 Cromwell Rd, London SW7 4DN, UK
IMMUNOGENICITY
Conference: Monday 13th & Tuesday 14th June 2016, Holiday Inn Kensington Forum, London, UK Workshops: Wednesday 15th June 2016, London, UK
4 WAYS TO REGISTER
www.immuno.co.uk
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor
South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK